" class="wow_main_float_head_img">
Stem Cells Industry Data Book Covers Human Embryonic Stem Cells, Induced Pluripotent Stem Cells Production, Mesenchymal Stem Cells and Cancer Stem Cells Markets.
Grand View Research’s Stem Cells Industry databook is a collection of market sizing forecasts insights, market dynamics trends, opportunity assessment, regulatory technology framework, pricing intelligence, competitive benchmarking analyses, and macro-environmental analysis studies. Within the purview of the databook, such information is systematically analyzed and provided in the form of summary presentations and detailed outlook reports on individual areas of research.
Stem Cells Market Insights
The global stem cells market size was valued at USD 13,266.8 million in 2022 and is expected to expand at a compound annual growth rate (CAGR) of 9.74% from 2023 to 2030.
Adult stem cells held the largest share of 83.34% of the market in 2022 as these cells do not involve the destruction of embryos, which is the case in embryonic stem cells. Furthermore, there is no risk of graft rejection in the case of adult stem cells. Development of cell banking services and advancements in bio preservation and cryopreservation are expected to further boost the demand for adult stem cells. Lesser ethical concerns surrounding adult cells further propel the growth of this segment.
Regenerative medicine and drug discovery and development are two applications within the application segment. Increased approvals for clinical trials on stem cell therapies targeting various diseases has resulted in regenerative medicine segment capturing the larger market share of 90.17% in 2022. Longeveron LLC, for example, announced in June 2020 that Japan's Pharmaceutical and Medical Devices Agency (PMDA) had approved the start of Phase 2 clinical trial to evaluate the safety and efficacy of their mesenchymal stem cells that can be used to treat aging frailty.
The cell acquisition segment captured the highest revenue share of 33.67% of the market in 2022. Discovery of embryonic stem cells has paved way for development of novel treatments for several diseases. These cells are pluripotent in nature and can be used to differentiate many cell types in the body. However, obtaining embryonic cells directly from the embryo has raised ethical concerns.
Allogenic therapy segment captured the largest market share of 59.14% in 2022 with regards to revenue generation. Factors such as high pricing and growth in stem cell banking have contributed to the growth of this segment. Moreover, many cell therapy companies are shifting their business toward development of allogenic cell therapy products. This, in turn, is expected to result in the significant growth of this segment.
Pharmaceutical and biotechnology companies segment captured the largest market share of 53.76% in 2022. Some of the factors that can be attributed to the segment's share are rising prevalence of chronic disease, increase in clinical trials, upsurge in strategic activities along with improvements in healthcare services. For instance, in August 2022, StemCyte, Inc. obtained approval from U.S. FDA for their Phase II clinical trial for Post-COVID Syndrome using umbilical cord blood stem cell therapy.
Human Embryonic Stem Cells Market Insights
The global Human Embryonic Stem Cells market size was valued at USD 494.7 million in 2015. These are the pluripotent cells that possess the ability to get differentiated into all germ layers.
Applicability for inducing differentiation into a wide range of tissues is attributive to the largest share of regenerative medicine. The differentiated cells are further used for therapeutic applications in regenerative medicine.
hESC research is anticipated to have considerable potential in the treatment of disorders wherein cellular loss is known to occur. These disorders include Parkinson's disease, post-myocardial infarction, lung disorders, and Type 1 diabetes mellitus.
Access the Global Stem Cells Industry Data Book, 2022 to 2030, compiled with details like market sizing information forecasts, trade data, pricing intelligence, competition benchmarking, macro-environmental analyses, and regulatory technological framework studies
Induced Pluripotent Stem Cells Production Market Insights
The global induced pluripotent stem cells production market size was valued at USD 1.26 billion in 2021 and is expected to witness a compound annual growth rate (CAGR) of 9.2% from 2022 to 2030.
Based on process, the manual iPSC production segment held the largest market revenue share of 77.4% in 2021. The manual iPSC production process begins with the introduction of genes/transcription factors into rising somatic cells, a reprogramming step selection of iPSC colonies, expansion, and passaging of iPSCs. Companies with expertise in tissue procurement, gene introduction, RNA reprogramming, and cell culture and expansion drive revenue generation in this segment.
The cell culture segment dominated the market and accounted for the largest revenue share of 37.2% in 2021. Cell culture workflow is inclusive of revenues generated from iPSC harvest products, expansion products, and differentiation products; thus contributing to the market relevance of this segment.
Based on product, the consumables and kits segment held the largest revenue share in the market in 2021. The never-ceasing research and development activities in the iPSCs space are driving the demand for various consumables kits.
In 2021, the drug development and discovery segment generated the highest revenue of USD 546.4 million in the market. As the world is witnessing a rise in chronic diseases, The Partnership to Fight Chronic Disease (PFCD) estimated that more than 130 million Americans are affected with chronic diseases like diabetes, asthma, heart problems, and cancer. PFCD also stated that more than 1 in 2 American adults lives with one chronic disease and about 1 in 3 suffers from two or more chronic diseases.
Based on end-user, the biotechnology and pharmaceutical companies segment dominated the market and accounted for a revenue share of 59.3% in 2021. The availability and adoption of various kits, consumables, and instruments along with iPSCs products are driving the revenue generation in this segment. To utilize the market opportunity of the stem cell-based therapy market, biotechnology and pharmaceutical companies are boosting new product developments via intensive RD efforts.
Mesenchymal Stem Cells Market Insights
The global mesenchymal stem cells market size was valued at USD 2.4 billion in 2020 and is expected to expand at a compound annual growth rate (CAGR) of 12.6% from 2021 to 2028.
The products segment dominated the market and accounted for the largest revenue share of 79.1% in 2020. Among the products, the cells and cell lines segment has emerged as a key contributor to the segment’s revenue.
The allogeneic MSCs segment dominated the market and accounted for the largest revenue share of 54.3% in 2020. This is attributed to the high safety profile of allogeneic mesenchymal stem cells in clinical applications. Additionally, implantation of allogeneic MSCs is set to emerge as a pioneering cell-based therapeutic approach owing to the associated low immunogenicity coupled with immunosuppressive properties.
The bone marrow segment dominated the market and accounted for the largest revenue share of 25.8% in 2020. Bone marrow is a major source of isolation for mesenchymal stem cells. These cells have multilineage differentiation potential and are able to differentiate into bones, cartilage, tendons, fibroblasts, fat, cardiac muscle cells, and endothelial cells.
The cardiovascular diseases segment dominated the Mesenchymal Stem Cells (MSCs) market and accounted for the largest revenue share of 22.0% in 2020. Several pre-clinical studies have shown that the transplantation of mesenchymal stem cells improves cardiovascular repair, which has strengthened the penetration of MSCs in cardiovascular disease indications.
The disease modelling application segment dominated the market and accounted for the largest revenue share of 35.8% in 2020. The use of cellular disease models with patient-specific MSCs provides an ideal tool for pathological research. The mesenchymal stem cells derived from patient Induced Pluripotent Stem Cells serve as a potential disease modelling tool.
Cancer Stem Cells Market Insights
The global cancer stem cells market size was valued at USD 679.5 million in 2016. The market is expected to expand at a CAGR of 9.98% during the forecast period.
Understanding the biology of these cells and their role in management of tumor progression, the market can be segmented into two models of tumor treatment based on the mode of action. The first model incorporates targeted CSCs using monoclonal antibodies, recombinant proteins, nanomaterials, and other natural compounds.
The report has focused on the use of stem cells against a wide spectrum of tumor forms including breast, blood, lung, brain, colorectal, pancreas, and bladder, liver, head neck, ovarian, prostate, and gastric tumor.
Out of all the tumor forms, breast cancer commanded the leading share of the overall revenue in 2016 owing to its rising incidence and the presence of a relatively large number of stem cell therapeutics for this tumor type.
Stem Cells Market – Global Industry Segmentation
Global Stem Cells Market: Product Outlook
- Adult Stem Cells (ASCs)
- Hematopoietic
- Mesenchymal
- Neural
- Epithelial/Skin
- Others
- Human Embryonic Stem Cells (HESCs)
- Induced Pluripotent Stem Cells (iPSCs)
- Very Small Embryonic Like Stem Cells
Global Stem Cells Market: Application Outlook
- Regenerative Medicine
- Neurology
- Orthopedics
- Oncology
- Hematology
- Cardiovascular and Myocardial Infraction
- Injuries
- Diabetes
- Liver Disorder
- Incontinence
- Others
- Drug Discovery and Development
Global Stem Cells Market: Technology Outlook
- Cell Acquisition
- Bone Marrow Harvest
- Umbilical Blood Cord
- Apheresis
- Cell Production
- Therapeutic Cloning
- In-vitro Fertilization
- Cell Culture
- Isolation
- Cryopreservation
- Expansion and Sub-Culture
Global Stem Cells Market: Therapy Outlook
- Autologous
- Allogenic
- Global Stem Cells Market: Therapy Outlook
- Pharmaceutical and Biotechnology Companies
- Hospitals Cell Banks
- Academic Research Institutes
Human Embryonic Stem Cells Application Outlook
- Regenerative medicine
- Stem cell biology research
- Tissue engineering
- Toxicology testing
Induced Pluripotent Stem Cells Production Process Outlook
- Manual iPSC Production Process
- Automated iPSC Production Process
Induced Pluripotent Stem Cells Production Workflow Outlook
- Reprogramming
- Cell Culture
- Cell Characterization / Analysis
- Engineering
- Others
Induced Pluripotent Stem Cells Production Product Outlook
- Instruments/ Devices
- Automated Platforms
- Consumables Kits
- Media
- Kits
- Others
- Services
Induced Pluripotent Stem Cells Production Application Outlook
- Drug Development and Discovery
- Regenerative Medicine
- Toxicology Studies
- Others
Induced Pluripotent Stem Cells Production End-user Outlook
- Research Academic Institutes
- Biotechnology Pharmaceutical Companies
- Hospitals Clinics
Mesenchymal Stem Cells (MSCs) Product Services Outlook
- Products
- Workflow Type
- Cell Sourcing Isolation
- Culture Cryopreservation
- Differentiation
- Characterization
- Product Type
- Cells Cell Lines
- Kits, Media, Reagents
- Others
- Workflow Type
- Services
Mesenchymal Stem Cells (MSCs) Type Outlook
- Autologous
- Allogeneic
Mesenchymal Stem Cells (MSCs) Source of Isolation Outlook
- Bone Marrow
- Cord Blood
- Peripheral Blood
- Fallopian Tube
- Fetal Liver
- Lung
- Adipose Tissues
Mesenchymal Stem Cells (MSCs) Indication Outlook
- Bone And Cartilage Repair
- Cardiovascular Disease
- Inflammatory And Immunological Diseases
- Liver Diseases
- Cancer
- GvHD
- Others
Mesenchymal Stem Cells (MSCs) Application Outlook
- Disease Modelling
- Drug Development Discovery
- Stem Cell Banking
- Tissue Engineering
- Toxicology Studies
- Others
Cancer Stem Cells Mode Of Action Outlook
- Targeted Cancerous Stem Cells (CSCs)
- By Anti-Cancer Stem Cell Therapeutics
- Pathway Inhibitors
- WNT Signaling Pathway
- Hedgehog Signaling Pathway
- Notch Signaling Pathway
- Others
- Surface Marker-based
- Immuno-evasion Targeting Tumor Microenvironment
- Nanoparticle-based Therapies
- Others
- Pathway Inhibitors
- By Products
- Cell Culturing
- Cell Separation
- Cell Analysis
- Molecular Analysis
- Others
- By Anti-Cancer Stem Cell Therapeutics
- Stem Cell-based Cancer Therapy
- Autologous Stem Cell Transplant
- Allogeneic Stem Cell Transplant
Cancer Stem Cells Cancer Forms Outlook
- Breast Cancer
- Blood Cancer
- Lung Cancer
- Brain Cancer
- Colorectal Cancer
- Pancreatic Cancer
- Bladder Cancer
- Liver Cancer
- Other Cancer
Order your copy of the Free Sample of “Stem Cells Industry Data Book - Human Embryonic Stem Cells, Induced Pluripotent Stem Cells Production, Mesenchymal Stem Cells and Cancer Stem Cells Market Size, Share, Trends Analysis, And Segment Forecasts, 2023 - 2030” Data Book, published by Grand View Research
Stem Cells Industry Data Book Regional Outlook
- North America
- U.S.
- Canada
- Europe
- U.K.
- Germany
- France
- Italy
- Denmark
- Sweden
- Norway
- Rest of Europe
- Asia Pacific
- China
- Japan
- India
- South Korea
- Australia
- Thailand
- Rest of Asia Pacific
- Latin America
- Brazil
- Mexico
- Argentina
- Rest of Latin America
- Middle East Africa (MEA)
- South Africa
- United Arab Emirates
- Saudi Arabia
- Kuwait
- Rest of Middle East Africa
Stem Cells Industry Data Book Competitive Landscape
Competitive rivalry in the stem cell industry is high due to the presence of a large number of both well-established players and small- to mid-sized companies as well as CROs in the market space.
Key players operating in the stem cells industry are –
- STEMCELL Technologies Inc.
- Advanced Cell Technology Inc.
- Cellular Engineering Technologies Inc.
- CellGenix GmbH
- Angel Biotechnology
- PromoCell GmbH
- Kite Pharma
- Lonza
- Cellartis AB
- Celgene Corporation
- Brainstorm Cell Therapeutics
- Osiris Therapeutics
- Genea Biocells
- Waisman Biomanufacturing
- Bioheart Inc.
- Tigenix
- Caladrius Biosciences
- Gamida Cell
Go through the table of content of Stem Cells Industry Data Book to get a better understanding of the Coverage Scope of the study
About Grand View Research
Grand View Research, U.S.-based market research and consulting company, provides syndicated as well as customized research reports and consulting services. Registered in California and headquartered in San Francisco, the company comprises over 425 analysts and consultants, adding more than 1200 market research reports to its vast database each year. These reports offer in-depth analysis on 46 industries across 25 major countries worldwide. With the help of an interactive market intelligence platform, Grand View Research helps Fortune 500 companies and renowned academic institutes understand the global and regional business environment and gauge the opportunities that lie ahead.
Contact:
Sherry James
Corporate Sales Specialist, USA
Grand View Research, Inc.
Phone: 1-415-349-0058
Toll Free: 1-888-202-9519
Email: sales@grandviewresearch.com
Web: https://www.grandviewresearch.com/sector-reports-list
